Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.

Xu XL, Bao QC, Jia JM, Liu F, Guo XK, Zhang MY, Wei JL, Lu MC, Xu LL, Zhang XJ, You QD, Sun HP.

Sci Rep. 2016 Jan 8;6:19004. doi: 10.1038/srep19004.

2.

Biomarkers in triple negative breast cancer: A review.

Yadav BS, Chanana P, Jhamb S.

World J Clin Oncol. 2015 Dec 10;6(6):252-63. doi: 10.5306/wjco.v6.i6.252. Review.

3.

A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species.

Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J 3rd, Becker MW, Rudin CM, Melnick A, Levine RL, Roboz GJ, Nimer SD, Chiosis G, Guzman ML.

Cell Rep. 2015 Dec 15;13(10):2159-73. doi: 10.1016/j.celrep.2015.10.073. Epub 2015 Nov 25.

4.

HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms.

Sevin M, Girodon F, Garrido C, de Thonel A.

Mediators Inflamm. 2015;2015:970242. doi: 10.1155/2015/970242. Epub 2015 Oct 15. Review.

5.

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.

J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.

PMID:
26529251
6.

In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.

Prchal-Murphy M, Witalisz-Siepracka A, Bednarik KT, Putz EM, Gotthardt D, Meissl K, Sexl V, Müller M, Strobl B.

Oncoimmunology. 2015 May 26;4(11):e1047579. eCollection 2015 Nov.

7.

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.

Akahane K, Sanda T, Mansour MR, Radimerski T, DeAngelo DJ, Weinstock DM, Look AT.

Leukemia. 2016 Jan;30(1):219-28. doi: 10.1038/leu.2015.222. Epub 2015 Aug 12.

PMID:
26265185
8.

Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.

Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, Deshaies RJ, Land H, Zhao J.

Oncotarget. 2015 Jun 20;6(17):14796-813.

9.

Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening.

Theodoraki MA, Rezende CO Jr, Chantarasriwong O, Corben AD, Theodorakis EA, Alpaugh ML.

Oncotarget. 2015 Aug 28;6(25):21255-67.

10.

An unexpected alliance between stress responses to drive oncogenesis.

Keenan MM, Ding CK, Chi JT.

Breast Cancer Res. 2014 Nov 6;16(6):471. doi: 10.1186/s13058-014-0471-1.

11.

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Patel HJ, Patel PD, Ochiana SO, Yan P, Sun W, Patel MR, Shah SK, Tramentozzi E, Brooks J, Bolaender A, Shrestha L, Stephani R, Finotti P, Leifer C, Li Z, Gewirth DT, Taldone T, Chiosis G.

J Med Chem. 2015 May 14;58(9):3922-43. doi: 10.1021/acs.jmedchem.5b00197. Epub 2015 Apr 22.

PMID:
25901531
12.

Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance.

Shahinas D, Folefoc A, Pillai DR.

Pathogens. 2013 Feb 4;2(1):33-54. doi: 10.3390/pathogens2010033. Review.

13.

Standard of care and promising new agents for triple negative metastatic breast cancer.

Mancini P, Angeloni A, Risi E, Orsi E, Mezi S.

Cancers (Basel). 2014 Oct 24;6(4):2187-223. doi: 10.3390/cancers6042187. Review.

14.

HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization.

Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Fröhling S, Scholl C, Seufferlein T.

Cancer Res. 2014 Dec 1;74(23):7125-36. doi: 10.1158/0008-5472.CAN-14-1017. Epub 2014 Oct 8.

15.

Selective targeting of the stress chaperome as a therapeutic strategy.

Taldone T, Ochiana SO, Patel PD, Chiosis G.

Trends Pharmacol Sci. 2014 Nov;35(11):592-603. doi: 10.1016/j.tips.2014.09.001. Epub 2014 Sep 25. Review.

16.

Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention.

Carman A, Kishinevsky S, Koren J 3rd, Lou W, Chiosis G.

J Alzheimers Dis Parkinsonism. 2013 Apr;2013(Suppl 10). pii: 007.

17.
18.

Getting folded: chaperone proteins in muscle development, maintenance and disease.

Smith DA, Carland CR, Guo Y, Bernstein SI.

Anat Rec (Hoboken). 2014 Sep;297(9):1637-49. doi: 10.1002/ar.22980. Review.

19.

Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.

Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W.

PLoS One. 2014 Jun 4;9(6):e98370. doi: 10.1371/journal.pone.0098370. eCollection 2014.

20.

Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.

Al-Ejeh F, Miranda M, Shi W, Simpson PT, Song S, Vargas AC, Saunus JM, Smart CE, Mariasegaram M, Wiegmans AP, Chenevix-Trench G, Lakhani SR, Khanna KK.

Oncotarget. 2014 May 30;5(10):3145-58.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk